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ABSTRACT
Background: Liver biopsy (LB) is still considered to be the gold standard for assessment 
of liver fibrosis.
Objectives: To evaluate the effectiveness of various non-invasive methods for predict-
ing liver fibrosis, including transient elastography (TE), APRI score, Lok score, Forns 
score, FIB-4 score, Fibrosis Index, King score, and Bonacini score, in comparison with 
the effectiveness of LB and to create a new scoring system for fibrosis prediction.
Patients and Methods: This study included 212 patients with chronic HCV hepatitis. LB, 
TE, and various biological tests were performed during a single hospital visit. Using 
established formulae, data from these tests were used to create scores for assessment 
of liver fibrosis.
Results: The results of all the tests showed significant correlation with histological fi-
brosis. TE results (r = 0.62), King score (r = 0.57), and APRI score (r = 0.56) showed the 
closest correlation with severity of fibrosis. The following formula was derived from 
our data by multiple regression: Predicted liver fibrosis score (PLF score) = 0.956 + 
0.084 × TE – 0.004 × King score + 0.124 × Forns score + 0.202 × APRI score. A direct cor-
relation (r = 0.68) was found between the PLF score and liver fibrosis. The cut-off values 
of the PLF score for various stages of fibrosis were: F ≥ 1, 1.77 (Area under ROC curve 
(AUROC) = 0.76); F ≥ 2, 2.18 (AUROC = 0.78); F ≥ 3, 2.47 (AUROC = 0.86); and F = 4, 2.98 
(AUROC = 0.97).
Conclusions: We found that our newly developed PLF score, which is derived from the 
scores of multiple tests, is more strongly correlated with fibrosis than each compo-
nent score used individually. The PLF score is more effective than TE for predicting se-
vere fibrosis, but they have similar effectiveness in predicting liver cirrhosis.
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1. Background
Chronic hepatitis, caused by hepatitis C virus (HCV), is 
an important public health problem. In 1999, the World 
Health Organization estimated the global prevalence of 
HCV infection to be approximately 3%, with the disease 
affecting around 170 million people (1). In Europe, the 
prevalence is estimated to be 1%, but with large variations 
between  countries  (2).  In  Romania,  the  prevalence  is 
estimated to be 3.23% (3). The assessment of liver fibrosis 
is important for the staging and prognosis of chronic Hepat Mon. 2011;11(7):548-555
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hepatitis, and liver biopsy (LB) is still considered to be the 
gold standard for this purpose (4-6). Recently, noninvasive 
approaches  employing  ultrasound-based  technology, 
including  transient  elastography  (TE)-FibroScan  (7-9), 
real-time  elastography  (10-14),  and  acoustic  radiation 
force impulse elastography (ARFI) (15-19), and serological 
methods,  most  notably,  FibroTest-ActiTest,  have  been 
developed for evaluation of liver fibrosis (20-24).
TE is performed with the Fibroscan® device (Echosens, 
Paris,  France),  which  consists  of  a  5-MHz  ultrasound 
transducer probe mounted on the axis of a vibrator. The 
vibrator generates a completely painless vibration (with 
a frequency of 50 Hz and amplitude of 2 mm), which 
generates an elastic share wave propagating through the 
skin and the subcutaneous tissue to the liver. The velocity 
of the wave is directly related to tissue stiffness (8, 9). ARFI 
elastography is based on the principle that compression 
of the examined tissue induces less strain in hard than 
in  softer  tissues.  The  ultrasound  probe  automatically 
produces an acoustic “push” pulse that generates shear-
waves,  which  propagate  into  the  tissue.  Using  image-
based  localization  and  proprietary  ARFI  technology, 
shear wave speed and tissue depth may be quantified in 
a precise anatomical region of interest predefined by the 
system. Propagation speed, measured in meters/second 
(m/s), is displayed on a screen and increases with fibrosis 
severity (17, 18).
Other biological scores, such as APRI score, Lok score, 
Forns  score,  FIB-4  score,  FI-Fibrosis  Index  score,  King 
score, and Bonacini score are very simple to calculate 
using  standard  biological  tests  and  are  used  in  daily 
practice (25-31). Currently, TE is the most commonly used 
non-invasive  method  for  assessment  of  liver  fibrosis, 
particularly in Europe. TE has not only been validated in 
HCV chronic hepatitis but also in HBV chronic hepatitis, 
non-alcoholic  steatohepatitis  (NASH),  and  post-
transplant patients with primary biliary cirrhosis (PBC) 
(9, 32-34).
2. Objectives
The aim of this study was to evaluate the effectiveness of 
various noninvasive methods for predicting liver fibrosis, 
including  TE-FibroScan,  APRI  score,  Lok  score,  Forns 
score, FIB-4 score, FI (Fibrosis Index) score, King score, 
and Bonacini score, in comparison with the effectiveness 
of current gold standard of LB. On the basis of the results, 
we aimed to create a new scoring system for predicting 
liver fibrosis with increased sensitivity, specificity, and 
accuracy than the individual scoring systems.
3. Patients and Methods
3.1. Patients
This was retrospective study that included 212 patients 
with chronic HCV hepatitis (143 women and 69 men; mean 
age 49.9 ± 9.9 years) admitted to our department from 
January 2008 to March 2010. The patients were anti-HCV 
positive for at least 6 months and had detectable levels of 
HCV-RNA by RT-PCR. All patients underwent abdominal 
ultrasound,  LB,  liver  stiffness  (LS)  measurements  by 
means of TE, and biological tests. Informed consent was 
obtained from all patients, and the study protocol was 
approved by the local ethics committee.
3.2. Liver biopsy
Echo-assisted LB was performed in all patients by using 
modified Menghini needles (1.4 and 1.6 mm in diameter). 
Only LB fragments including at least 8 portal tracts were 
considered  adequate  for  pathological  interpretation 
and were included in our study. The LBs were assessed 
according  to  the  Metavir  scoring  system  by  a  senior 
pathologist blinded to the results of the LS measurements. 
Fibrosis was staged on a 0–4 scale: F0, no fibrosis; F1, portal 
fibrosis without septa; F2, portal fibrosis and few septa 
extending into lobules; F3, numerous septa extending to 
adjacent portal tracts or terminal hepatic venules; and 
F4, cirrhosis.
3.3. Transient elastography
LS was measured by means of TE using a FibroScan device 
(EchoSens-Paris, France). In each patient, we performed 
10 valid TE measurements, after which the median value 
was  calculated  and  the  results  were  expressed  in  kPa. 
In this study, we included only LS measurements with 
a  success  rate  (the  ratio  of  the  number  of  successful 
acquisitions over the total number of acquisitions) of at 
least 60% and an interquartile range (IQR) lower than 30%. 
(IQR is the difference between the 75th and 25th percentile, 
essentially the range of the middle 50% of the data).
3.4. Serological score
Bioassays were performed by venous blood sampling 
and  were  processed  in  our  hospital’s  laboratories.  All 
bioassays were routine biological tests and the following 
normal values (NV) were used: aspartate aminotransferase 
(AST), NV = 5–34 U/L; alanine aminotransferase (ALT), NV 
=  10–35  U/L;  gamma  glutamyl  transpeptidase  (GGTP), 
NV  =  12–64  U/L;  platelet  count,  NV  =  150000–450000/
mm³; cholesterol, NV < 200 mg%; serum albumin, NV = 
3.5–5 g/dL; and INR, NV = 0.88–1.10. On the basis of these 
biological tests, we calculated the following scores for 
predicting liver fibrosis:
APRI score = [(AST/upper limit NV AST) ×100]/number of 
platelets (10⁹/l) (25)
Lok score: log odds = -5.56 - 0.0089 × number of platelets 
(10³/mm³) + 1.26 × (AST/ALT) + 5.27 × INR
Lok = [exp (log odds)]/ [1 + exp (log odds)] (26)
Forns score = 7.811 - 3.131 × ln [number of platelets (10⁹/l)] 
× 0.781 ln [GGTP (U/L)] + 3.467 × ln [age (years)] - 0.014 
[cholesterol (mg/dl)] (27)
FIB-4  score  =  [age  (years)]  ×  AST  (U/L)]/[number  of 
platelets (10⁹/L)] × ALT (U/L)½] (28)
FI score (fibrosis index) = 8 - 0.01 × number of platelets Hepat Mon. 2011;11(7):548-555
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(10⁹/L) - albumin (g/dL) (29)
King score = age (years) × AST (U/L) × INR/number of 
platelets (10⁹/L) (30)
Bonacini score: different points are given (which are 
added together) according to the value of AST/ALT, INR 
and platelet count (31) (Table 1).
3.5. Statistical analysis
Data were collected and tabulated in a Microsoft Excel 
file. Statistical analysis was performed using the MedCalc 
program  and  WINK  Statistical  Data  Analysis  Research 
Software. The LS values and the scores were expressed 
as  means  and  standard  deviation.  Spearman’s  rank 
correlation  coefficient  was  used  to  assess  correlations 
between histological findings and the various predictive 
scores  of  liver  fibrosis.  Two-way  ANOVA  was  used  to 
compare mean values for different stages of fibrosis in 
the new scoring system. Multiple regression was used 
to calculate the new liver fibrosis scores. The diagnostic 
performance  of  the  new  scoring  system  was  assessed 
using receiver operating characteristic (ROC) built for 
the detection of fibrosis: (F ≥ 1, Metavir score), significant 
fibrosis (F ≥ 2), severe fibrosis (F ≥ 3), and cirrhosis (F = 4). 
Optimal cut-off values were chosen so that sensitivity and 
specificity were maximal. Sensitivity and specificity were 
calculated according to standard methods. Further, 95% 
confidence intervals were calculated for each predictive 
test and were used to compare AUROC curves.
4. Results
According to the Metavir scoring system, the severity 
of liver fibrosis in the study group of 212 patients with 
chronic hepatitis C was graded as follows: 1.4% (3 patients) 
had  no  fibrosis  (F  =  0);  8.0%  (17  patients)  had  stage  1 
fibrosis (F = 1); 44.8% (95 patients) had stage 2 fibrosis (F = 
2); 31.6% (67 patients) had stage 3 fibrosis (F = 3); and 14.2% 
(30 patients) had cirrhosis (F = 4). The average fragment 
size  obtained  by  LB  was  3.35  ±  0.90  cm.  All  methods 
used  for  predicting  liver  fibrosis  were  directly,  and 
significantly, correlated with histological findings, but 
TE (r = 0.62), King score (r = 0.57), and APRI score (r = 0.56) 
had the strongest correlation with fibrosis severity (Table 
2). We chose the 4 tests that had the strongest correlation 
to severity of fibrosis in histological samples, and from 
these  data,  we  used  multiple  regression  to  develop  a 
new score (PLF score) for predicting the severity of liver 
fibrosis. The formula employed in this analysis was as 
follows:
PLF score = 0.956 + 0.084 × TE - 0.004 × King score + 
0.124 × Forns score + 0.202 × APRI score.
A direct correlation (Spearman co-efficient; r = 0.68) was 
found to exist between our new scoring system and the 
Metavir scoring system (P < 0.0001). The correlation of 
the new scoring system with the severity of fibrosis was 
better than that of the other methods alone. The mean 
PLF scores for different stages of fibrosis ranged from 1.93 
± 0.45 for F0 to 3.64 ± 0.55 for F4 (Table 3). While there was 
no significant difference between mean PLF scores for F0 
and F1 stages of fibrosis (P = 0.77), statistically significant 
differences were apparent for F1 vs. F2 (P = 0.01), F2 vs. F3 
(P < 0.001), and F3 vs. F4 (P < 0.001). Using the ROC curve, 
we calculated the cut-off PLF scores for different stages of 
liver fibrosis (Table 4).
The PLF score had a better predictive value than the TE 
score for significant fibrosis (F ≥ 2: AUROC = 0.78 vs. 0.74 
[P = 0.02]), and for severe fibrosis (F ≥ 3: AUROC = 0.86 vs. 
0.81 [P = 0.003]). However, for cirrhosis, the predictive 
values were similar (AUROC = 0.97 vs. 0.97; P = 0.28) (Table 
5). The PLF score also had a better predictive value than the 
King score for severe fibrosis (F ≥ 3: AUROC = 0.86 vs. 0.81 
[P = 0.02]) and for cirrhosis (F = 4: AUROC = 0.97 vs. 0.88 
[P = 0.001]). However, the 2 tests had similar effectiveness 
Parameter 0 points 1 point 2 points 3 points 4 points 5 points 6 points
INR < 1.1 1.1-1.4 > 1.4 _ _ _ _
ALT/AST > 1.7 1.7-1.2 1.19-0.6 < 0.6 _ _ _
Platelets (x10³/mm ³) > 340 340-280 279-220 219-160 159-100 99-40 < 40
Table 1. Bonacini score
Test Spearman's rank correlation coefficient  P value
TE-FibroScan 0.62 < 0.0001
King score 0.57 < 0.0001
APRI score 0.56 < 0.0001
Forns score 0.55 < 0.0001
Lok score 0.49 < 0.0001
FI a score 0.49 < 0.0001
FIB-4 score 0.45 < 0.0001
Bonacini score 0.42 < 0.0001
Table 2. Correlation between different tests and liver fibrosis (assessed according Metavir score)
a FI: Fibrosis indexHepat Mon. 2011;11(7):548-555
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in predicting significant fibrosis (F ≥ 2: AUROC = 0.78 vs. 
0.75 [P = 0.07]) (Table 5). The value of the PLF score was 
significantly higher than the Forns score for predicting 
significant fibrosis (F ≥ 2: AUROC = 0.78 vs. 0.73 [P = 0.01]), 
severe fibrosis (F ≥ 3: AUROC = 0.86 vs. 0.80 [P = 0.006]) 
and cirrhosis (F = 4: AUROC = 0.97 vs. 0.85 [P = 0.0001]) 
(Table 5). The PLF score was also better than the APRI score 
for predicting significant fibrosis (F ≥ 2: AUROC = 0.78 vs. 
0.68 [P = 0.003]) and cirrhosis (F = 4: AUROC = 0.97 vs. 0.87 
[P = 0.0006]), while the 2 tests were similarly effective in 
predicting severe fibrosis (F ≥ 3: AUROC = 0.86 vs.0.82 [P = 
0.058]) (Table 5).
5. Discussion
While  noninvasive  methods  are  being  increasingly 
used  for  the  assessment  of  liver  fibrosis,  clinicians 
must  choose  between  different  serological  tests  (35) 
and elastographic methods. The APRI scoring system is 
not expensive and is accessible to all clinicians. A meta-
analysis (25) conducted in 2007 showed that with a cut-
off value of 0.5, APRI scores had 81% sensitivity (Se) and 
50% specificity (Sp) for predicting significant fibrosis (F 
≥ 2, Metavir score), and with a cut-off value of 1, they had 
76% Se and 71% Sp for predicting cirrhosis. Using these 
cut-off values in the current study, we obtained 67.7% Se, 
70% Sp, 95.5% positive predictive value (PPV), 70% negative 
predictive value (NPV), and 67.9% accuracy for predicting 
significant  fibrosis.  For  prediction  of  cirrhosis,  we 
obtained 80% Se, 74.1% Sp, 33.8% PPV, 95.7% NPV, and 75% 
accuracy. The Lok score was originally proposed by Lok 
and co-workers (26). According to the authors, a cut-off 
value of < 0.2 excludes the diagnosis of liver cirrhosis 
(7.8% of patients wrongly classified) and a value greater 
than 0.5 predicts the diagnosis of liver cirrhosis (14.8% of 
patients wrongly classified). In our study, only 1 patient 
with  liver  cirrhosis  had  a  Lok  score  <  0.2  (3.3%  of  the 
patients with cirrhosis were incorrectly classified) and 4 
patients without cirrhosis had a Lok score > 0.5 (2.1% of 
patients without cirrhosis were incorrectly classified).
According  to  published  studies,  the  accuracy  of  the 
Forns score for predicting significant fibrosis ranges from 
50% to 83% (27, 36). This scoring system was initially used 
in HIV-HCV co-infected patients and was subsequently 
validated in HCV patients. With a cut-off value of 6.9 for 
the presence of significant fibrosis, 96% of patients were 
correctly classified (37). In our study group, only 59.2% of 
patients were classified correctly using this cut-off value. 
The  FIB-4  score  was  also  originally  developed  for  HIV-
HCV co-infected  patients but has subsequently proved 
effective for predicting severe fibrosis in HCV patients (F3 
and F4) with an AUROC of 0.85. Using a cut-off value of < 
1.45, the FIB-4 score excludes the presence of severe fibrosis 
with a NPV of 94.7% (74% Se and 80% Sp) and with a cut-off 
value greater than 3.25, it can confirm the presence of 
severe fibrosis with a PPV of 82% (37.6% Se and 78% Sp) (28, 
38). In the current study, using the same cut-off value for 
prediction of severe fibrosis, we obtained 21.6% Se, 99.1% 
Sp, 95.4% PPV, 60% NPV, and 63.6% accuracy. In a previous 
study, using a cut-off value of < 2.10, the FI score had 66.8% 
Se and 78.8% PPV for predicting F0–F1 fibrosis, and 68.5% 
sensitivity and 68.6% PPV in the validation group (29). In 
addition, with a cut-off value of ≥ 3.30, FI had 67.7% Se and 
75% PPV for predicting cirrhosis, while the sensitivity was 
70.8% and PPV was 81% in the validation group (29). In the 
current study, using these cut-off values for prediction of 
F0–F1 fibrosis, we obtained 95% Se, 21.8% Sp, 11.2% PPV, 97.6% 
NPV,  and  61%  accuracy.  For  predicting  liver  cirrhosis, 
FI had 13.3% Se, 99.4% Sp, 50% PPV, 84.1% NPV, and 85.8% 
accuracy. In a previous study, the King score predicted 
Fibrosis score Patients, No. Prediction of liver fibrosis score, Mean ± SD
F = 0 3 1.93 ± 0.45
F = 1 17 1.99 ± 0.32
F = 2 95 2.18 ± 0.27
F = 3 67 2.57 ± 0.41
F = 4 30 3.64 ± 0.55
Table 3. The mean values of PLF score for different stages of fibrosis (according to Metavir score)
fibrosis stage Cut-off value AUROC a Se b, %  Sp c, % PPV d, %  NPV e, %  Accuracy, % 
F ≥ 1 1.77 0.76 95.6 66.6 99.5 18.1 95.2
F ≥ 2 2.18 0.78 71.3 75 96.4 21.4 71.6
F ≥ 3 2.47 0.86 71.1 89.5 85.1 78.6 81.1
F = 4 2.98 0.97 96.6 93.4 70.7 99.4 93.8
Table 4. Cut-off values of PLF score for different stages of fibrosis (according to the Metavir score system)
a AUROC:  Area under ROC curve
b Se: Sensivity
c Sp: Specificity
d PPV: Positive predictive value
e NPV: Negative predictive valueHepat Mon. 2011;11(7):548-555
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cirrhosis with 86% Se, 80% Sp, and 96% NPV using a cut-off 
value ≥ 16.7 (30). In the current study, we obtained 90% 
Se, 74.1% Sp, 36.4% PPV, 97.8% NPV, and 76.4% accuracy. The 
King score was also found to be the serological test that 
had the strongest correlation with fibrosis (Spearman 
coefficient, r = 0.57).
The  Bonacini  formula  uses  the  Bonacini  score  (as 
calculated  above)  in  combination  with  an  evaluation 
of the liver surface by abdominal ultrasound to predict 
severe fibrosis and cirrhosis (31). An algorithm based on 
these data was used to predict cirrhosis and correctly 
classified 67% of patients as having high (> 75%) or low 
(< 10%) risk of cirrhosis, with only 33% of the patients 
requiring LB to confirm the diagnosis (31). TE is a method 
that    has    been  proven  to  be  useful  for  predicting 
significant fibrosis (F ≥ 2), with cut-off values ranging 
from 7.1 to 8.7 kPa, and cirrhosis (F = 4) with cut-off values 
ranging from 12.5 to 14.5 kPa (39, 40). In a meta-analysis 
published by Friedrich-Rust et al., using a cut-off value 
of  7.65  kPa,  TE  had  an  excellent  predictive  value  for 
the diagnosis of cirrhosis (AUROC = 0.94) and a good 
predictive value for significant fibrosis (AUROC = 0.85) 
(32). In a study by Sporea et al. (33), the optimal cut-off 
value for predicting significant fibrosis was 6.8 kPa, with 
56.5%  Se,  94.7%  Sp,  97.5%  PPV,  and  37.5%  NPV,  while  the 
optimal cut-off value for predicting severe fibrosis (F ≥ 
3) was 10.1 kPa (34). In another study published by Sirli 
et al. (41), using a cut-off value of 13.3 kPa, TE had 93.3% 
Se, 96.1% Sp, 73.7% PPV, and 99.2% NPV (AUROC = 0.97) for 
predicting cirrhosis. In the current study, using a cut-off 
value of 6.8 kPa for the presence of significant fibrosis, 
TE had 61.4% Se, 85% Sp, 97.5% PPV, 18.6% NPV, and 63.6% 
accuracy. Using a cut-off value of 10.1 kPa for the presence 
of severe fibrosis, TE had 52.5% Se, 93.9% Sp, 87.9% PPV, 
93.9% NPV, and 75% accuracy. With a cut-off value of 13.3 
kPa, TE had 93.3% Se, 97.2% Sp, 84.8% PPV, 98.8% NPV, and 
96.6% accuracy for predicting cirrhosis.
In  a  study  published  by  Sirli  et  al.  (41),  various  non-
invasive  methods  for  evaluation  of  liver  fibrosis  were 
compared to LB. An inverse correlation with fibrosis was 
obtained for platelet count (r = -0.484, P < 0.0001), and 
direct correlations were obtained for the APRI score (r = 
0.570, P < 0.0001), TE-FibroScan (r = 0.569, P < 0.0001), 
Forns score (r = 0.540, P < 0.0001), Lok score (r = 0.484, 
P < 0.0001), and FIB-4 score (r = 0.417, P < 0.0001). In the 
current study, the methods that correlated most strongly 
with fibrosis were TE-FibroScan (r = 0.62, P < 0.0001), King 
score (r = 0.57, P < 0.0001), APRI score (r = 0.56, P < 0.0001), 
and Forns score (r = 0.55, P < 0.0001). In a study performed 
by Friedrich-Rust (15), in which ARFI was compared to LB 
and blood markers in 86 patients with chronic hepatitis 
(HBV  or  HCV),  the  Spearman  correlation  co-efficients 
between  histologically  determined  fibrosis  and  ARFI, 
TE, FibroTest, and APRI scores, were 0.71, 0.73, 0.66, and 
0.45  respectively,  and  these  values  were  statistically 
significant (P < 0.001).
In a study published in 2005 by Castera et al. (39), 183 
patients with chronic HCV hepatitis were evaluated by LB, 
TE, Fibrotest, and APRI. The AUROC curves for FibroScan, 
FibroTest, and APRI in prediction of significant fibrosis 
(F ≥ 2), severe fibrosis (F ≥ 3), and cirrhosis (F = 4) were 
respectively  0.83,  0.85,  and  0.78;  0.90,  0.90,  and  0.84; 
and 0.95, 0.87, and 0.83. The most effective prediction 
performance was obtained by combining the FibroScan 
and FibroTest scores with AUROC curves of 0.88 for F ≥ 
2, 0.95 for F ≥ 3, and 0.95 for F = 4. When the FibroScan 
Fibrosis 
stage
Difference 
between area
Standard error 95% CI d P value
AUROC a PLF b score vs. AUROC TE c
0.789 vs. 0.742
0.862 vs. 0.810
0.972 vs. 0.977
F ≥ 2
F ≥ 3
F = 4
0.0472
0.0524
0.00441
0.0298
0.0177
0.00412
0.0275 to 0.0828
0.0177 to 0.0871
-0.00367 to 0.0125
0.02
0.003
0.28
AUROC PLF score vs. AUROC King score
0.789 vs. 0.759
0.862 vs. 0.815
0.972 vs. 0.887
F ≥ 2
F ≥ 3
F = 4
0.030
0.0477
0.0847
0.0392
0.0218
0.0262
-0.0165 to 0.103
0.0058 to 0.0904
0.0331 to 0.136
0.07
0.02
0.001
AUROC PLF score  vs. AUROC Forns score
0.789 vs. 0.735
0.862 vs. 0.804
0.972 vs. 0.852
F ≥ 2
F ≥ 3
F = 4
0.054
0.0581
0.120
0.0314
0.0215
0.0305
0.0294 to 0.0936
0.1159 to 0.100
0.607 to 0.180
0.01
0.006
0.0001
AUROC PLF score  vs. AUROC APRI score
0.789 vs. 0.688
0.862 vs. 0.825
0.972 vs. 0.879
F ≥ 2
F ≥ 3
F = 4
0.101
0.037
0.0932
0.0377
0.0243
0.0272
0.0531 to 0.153
-0.00156 to 0.0935
0.0398 to 0.147
0.003
0.058
0.0006
Table 5. Comparation between AUROC curves for PLF scor and TE, King score, Forns score , APRI score for prediction of different stages of fibrosis (according to 
the Metavir score system)
a AUROC: Area under curve
b PLF: Predicted liver fibrosis score
c TE: Transient elastography
d CI: Confidence intervalHepat Mon. 2011;11(7):548-555
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and FibroTest results agreed, LB confirmed the diagnosis 
in 84% of cases for F ≥ 2, 95% for F ≥ 3, and 94% for F = 4. 
In  another  study  published  in  2010,  Castera  et  al.  (21) 
studied  2  algorithms  for  prediction  of  liver  fibrosis: 
one utilized TE and FibroTest and the other used APRI 
and FibroTest (SAFE biopsy). LB was also performed in 
all  patients.  Significant  fibrosis  (F  ≥  2)  was  present  in 
76% of patients and cirrhosis (F4) in 25%. TE failure was 
observed  in  8  cases  (2.6%).  For  significant  fibrosis,  the 
Castera  algorithm  prevented  the  need  for  23%  more 
liver  biopsies  (71.9%  vs.  48.3%,  respectively,  P  <  0.0001) 
than did SAFE biopsy, but its accuracy was significantly 
lower (87.7% vs. 97.0%, respectively; P < 0.0001). While the 
accuracy of the Castera algorithm in predicting cirrhosis 
was significantly higher than that of SAFE biopsy (95.7% 
vs. 88.7%, respectively; P < 0.0001), the number of liver 
biopsies required did not differ between the 2 algorithms 
(78.8% vs. 74.8%; P = NS).
Shahenn  published  a  meta-analysis  in  which  he 
compared  the  performances  of  TE  and  Fibrotest  (in 
patients with chronic HCV hepatitis) for prediction of 
liver fibrosis (42). Data were collected from 13 studies, 9 
for FibroTest (1679 patients) and 4 for TE (546 patients). 
In  heterogeneous  analyses  for  significant  fibrosis,  the 
AUROC curves for FibroTest and TE were 0.81 (95% CI, 0.78–
84) and 0.83 (0.03–1.00), respectively. At a threshold of 
approximately 0.60, the sensitivity and specificity of the 
FibroTest was 47% (35–59%) and 90% (87–92%), respectively. 
For  TE  (at  a  threshold  of  approximately  8  kPa),  the 
corresponding  values  were  64%  (50–76%)  and  87%  (80–
91%). However, the diagnostic accuracy of both measures 
was correlated with the prevalence of significant fibrosis 
and  cirrhosis  in  the  study  populations.  For  cirrhosis, 
the summary AUROC curves for FibroTest and FibroScan 
were 0.90 (95% CI, not calculable) and 0.95 (0.87–0.99), 
respectively.
In  a  study  published  in  2010  by  Cross  et  al.  (43),  187 
patients with chronic HCV hepatitis were evaluated on 
the basis of LB, TE, and King score. Liver fibrosis was scored 
using  the  Ishak  score,  with  significant  fibrosis  being 
defined as an Ishak score of F3-F6 and cirrhosis being 
defined as an Ishak score of F5-F6. The AUROC curves for 
TE, King score, and TE + King score for the diagnosis of 
Ishak F3-F6 were 0.83, 0.82, and 0.85, respectively, and 
those for the diagnosis of cirrhosis (F ≥ 5, Ishak score) 
were  0.96,  0.89,  and  0.93,  respectively.  The  NPVs  for 
diagnosis of cirrhosis using the optimal cut-off values 
for TE (10.05 kPa), King score (24.3), and both combined 
(26.1)  were  98%,  91%,  and  94%,  respectively.  In  a  study 
published by Wang et al. (44), 214 patients with chronic 
HCV  hepatitis,  88  patients  with  chronic  HBV  hepatitis 
and 18 patients with chronic HBV + HCV hepatitis were 
evaluated  by  LB,  TE,  and  ultrasonography  (US).  US 
scores,  including  those  obtained  after  assessment  of 
liver  surface,  liver  parenchyma,  intrahepatic  vessels, 
and  spleen  index,  were  used  to  assess  the  degree  of 
hepatic  fibrosis.  LS  measurements  as  determined 
by  TE  correlated  significantly  with  hepatic  fibrosis 
scores,  necro-inflammatory  activity,  and  US  scores  in 
multivariate analysis. The diagnostic accuracy of TE in 
the  prediction  of  all  HCV-related  fibrosis  scores  was 
significantly superior to that of US and was equal to that 
of TE and US combined. In a study published by Sporea 
et al. (45), 242 subjects (171 with LB and 71 with clinical, 
ultrasonographic, endoscopic, and/or laparoscopic signs 
of  cirrhosis)  were  evaluated  by  TE  and  ARFI.  A  direct 
correlation  was  found  between  TE  measurements  and 
fibrosis (r = 0.858), between ARFI and fibrosis (r = 0.784), 
and also between TE and ARFI (r = 0.740). The optimal 
cut-off value for prediction of significant fibrosis (F ≥ 2) 
was 7.1 kPa for TE (AUROC = 0.92, 80% Se, 95% Sp) and 1.2 
m/s for ARFI (AUROC = 0.90, 85% Se, 88% Sp) and that for 
prediction of cirrhosis (F = 4) was 13.8kPa for TE (AUROC 
= 0.98, 95% Se, 94% Sp) and 1.8 m/s for ARFI (AUROC = 0.92, 
91% Se, 87% Sp). When both values of TE and ARFI were 
higher than the cut-off values, they achieved 65% Se and 
98% Sp for prediction of significant fibrosis (F ≥ 2) and 
74% Se and 97% Sp for prediction of cirrhosis. In the cases 
in which one of the values was higher than the cut-off 
value, they achieved 90% Se and 84% Sp for prediction of 
significant fibrosis and 98% Se and 84% Sp for prediction 
of cirrhosis.
In  this  study,  there  was  no  significant  difference 
between the mean values of the PLF score for F0 and F1 
stages of fibrosis (P = 0.77), which may have been due to 
the small number of patients included in these 2 groups 
(3 patients with F0 and 1 with F1 in the LB group). However, 
the differences were statistically significant for F1 vs. F2 
(P = 0.01), F2 vs. F3 (P < 0.001), and F3 vs. F4 (P < 0.001). 
The PLF score had a better predictive value than did TE 
for significant fibrosis (F ≥ 2: AUROC = 0.78 vs. 0.74 [P = 
0.002]) and for severe fibrosis (F ≥ 3: AUROC = 0.86 vs. 0.81 
[P = 0.003]), while the predictive values for cirrhosis were 
similar: AUROC = 0.97 vs. 0.97 (P = 0.28). The PLF score 
also had better predictive values for different stages of 
fibrosis than did the King score (with the exception of F 
≥ 2, Metavir score), Forns score, and APRI score (with the 
exception of F ≥ 3, Metavir score). In future studies, we 
will validate the PLF score in other groups of patients. 
For prediction of F ≥ 1 using a cut-off value of 1.77, the 
PLF  score  had  95.6%  Se,  99.5%  PPV,  and  95.2%  accuracy. 
For prediction of significant fibrosis (F ≥ 2), with a cut-
off value of 2.18, the PLF score had a 96.4% PPV, while for 
prediction of fibrosis (F = 4), with a cut-off value of 2.98, 
the PLF score had 96.6% Se, 93.4% Sp, 99.4% NPV, and 93.8% 
accuracy. 
In conclusion, we have devised a new PLF scoring system, 
derived from TE and multiple serological tests, to predict 
the severity of liver fibrosis. PLF scores are more closely 
correlated with fibrosis than each of the individual tests 
when used alone (r = 0.68). While the new scoring system 
is  more  effective  than  TE  (FibroScan)  in  predicting 
significant and severe fibrosis, their predictive values for 
cirrhosis are similar.Hepat Mon. 2011;11(7):548-555
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